Asthma in the era of COVID-19

Sara Assaf; Henning Stenberg; Milos Jesenak; Svitlana P Tarasevych; Nicola A Hanania; Zuzana Diamant

doi:10.1016/j.rmed.2023.107373

Asthma in the era of COVID-19

Respir Med. 2023 Nov:218:107373. doi: 10.1016/j.rmed.2023.107373. Epub 2023 Aug 10.

Authors

Sara Assaf¹, Henning Stenberg², Milos Jesenak³, Svitlana P Tarasevych⁴, Nicola A Hanania⁵, Zuzana Diamant⁶

Affiliations

¹ Section of Pulmonary and Critical Care Medicine, University of New Mexico, Albuquerque, NM, USA. Electronic address: SAssaf@salud.unm.edu.
² Center for Primary Health Care Research, Lund University, Malmö, Sweden.
³ Departments of Pulmonology and Phthisiology and Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovak Republic.
⁴ Department of Respiratory Medicine, Zaans Medical Center, Zaandam, the Netherlands.
⁵ Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA.
⁶ Dept of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Belgium; Dept of Respiratory Medicine & Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Dept Clin Pharm & Pharmacol, Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. Electronic address: z.diamant@4gems.nl.

PMID: 37567514
DOI: 10.1016/j.rmed.2023.107373

Abstract

Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.

Keywords: Asthma; Biologicals; COVID-19; Long COVID; Phenotypes.

Publication types

Review

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Asthma* / diagnosis
COVID-19* / complications
COVID-19* / epidemiology
Comorbidity
Humans
SARS-CoV-2

Substances

Adrenal Cortex Hormones